PB 26 of 2023

National Health (IVF Program) Special Arrangement Amendment Instrument 2023 (No. 1)

National Health Act 1953

I, NIKOLAI TSYGANOV, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 100(2) of the *National Health Act 1953*.

Date 30 March 2023

NIKOLAI TSYGANOV
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division

Contents

1 Name

(1) This instrument is the *National Health (IVF Program) Special Arrangement Amendment Instrument 2023 (No. 1)*.

(2) This instrument may also be cited as PB 26 of 2023.

2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	**Column 2**	**Column 3**
Provisions	**Commencement**	**Date/Details**
1. *The whole of this instrument*	*1 April 2023*	*1 April 2023*

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 100(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (IVF Program) Special Arrangement 2015 (PB 60 of 2015)

[1] Schedule 1, entry for Follitropin Beta

substitute:

Follitropin beta	Solution for injection 300 I.U. in 0.36 mL multi-dose cartridge	Injection	Puregon 300 IU/0.36 mL	C(100)
			Recagon	C(100)
	Solution for injection 600 I.U. in 0.72 mL multi-dose cartridge	Injection	Puregon 600 IU/0.72 mL	C(100)
			Recagon	C(100)
	Solution for injection 900 I.U. in 1.08 mL multi-dose cartridge	Injection	Puregon 900 IU/1.08 mL	C(100)
			Recagon	C(100)

[2] Schedule 1, entry for Ganirelix

(a) *omit from the column headed "Form":* **Injection 250 micrograms (as acetate) in 0.5 mL pre filled syringe** *substitute:* **Injection 250 micrograms (as acetate) in 0.5 mL pre-filled syringe**

(b) *insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":*

			Ganirelix Theramex	D(100)